Lipid-lowering drugs have been shown to have profound actions beyond modulation of lipid profiles. Statins have been shown to reduce the levels of pro-inflammatory cytokines and markers of acute phase response including C-reactive protein and serum amyloid A. Fibrates have also shown to reduce interlukin-6 levels. Both groups of drugs seem to act through a peroxisomal proliferating activating receptor alpha mechanism to achieve these actions. In lupus, there is profound activation of cytokine production and the acute phase response and a markedly increased risk for the development of atherosclerosis. The role of lipid-lowering drugs in the management of both the acute and chronic sequelae of lupus needs to be explored.
Wood D , Durrington P , Poulter N , McInnes G , Rees A , Wray R on behalf of the Societies Joint British Recommendations on Prevention of Coronary Heart Disease in Clinical Practice . Heart1998; 80(Suppl 2): S1-S29 .
2.
Rubins HB , Robins SJ , Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol . New Engl J Med1999; 341: 410-418 .
3.
Cross JT , Benton JP . The roles of interleukin-6 and interleukin-10 in B-cell hyperactivity in systemic lupus erythematosus . Inflammation Res1999; 48: 255-261 .
4.
Robak E , Sysa-Jedrzejowska A , Stepien H , Robak T . Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus . Euro Cytokine Network1997; 8: 281-286 .
5.
Davas EM , Tsirogianni A , Kappou I , Karamitsos D , Economidou I , Dantis PC . Serum II-6, TNF-alpha, p55, srTNF-alpha, p75srTNF-alpha, srIL-2 alpha levels and disease activity in systemic lupus erythematosus . Clin Rheumatol1999; 18: 17-22 .
6.
Brink I , Thiele B , Burmesetr GR , Trebeljahr G , Emmrich F , Hiepe F . Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients with systemic lupus erythematosus . Lupus1999; 8: 723-730 .
7.
Sun KH , You CL , Tang SJ , Sun GH . Monoclonal anti-double stranded DNA antibody stimulates the expression of release of IL-1 beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis . Immunology2000; 99: 352-360 .
8.
Leong KH , Koh ET , Feng PH , Boey ML . Lipid profiles in patients with systemic lupus erythematosus . J Rheumatol1994; 21: 1264-1267 .
9.
Manzi S , Selzer F , Sutton-Tyrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus . Arthrit Rheum1999; 42: 51-60 .
10.
Wierzbicki AS . Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus . Lupus2000; 9: 194-201 .
11.
Aguilar-Salinas SA , Barrett H , Schonfeld G . Metabolic modes of action of statins in the hyperlipoproteinemias . Atherosclerosis1998; 141: 203-207 .
12.
Lennernas H , Fager G . Pharmacodynamics and pharmacokinetics of HMG-CoA reductase inhibitors . Clin Pharmacokin1997; 32: 403-425 .
13.
Zhang FL , Casey PJ . Protein prenylation: mechanisms and functional consequences . A Rev Biochem1996; 65: 241-269 .
14.
Ridker PM . Novel risk factors and markers for coronary disease . Adv Intern Med2000; 45: 391-418 .
15.
Morrow DA , Ridker PM . C-reactive protein, inflammation, and coronary risk . Med Clin N Am2000; 84: 149-161 .
16.
Rossen RD . HMG-CoA reductase inhibitors: a new class of anti-inflammatory drugs?J Am Coll Cardiol1997; 30: 1218-1219 .
17.
Pineda Torra I , Gervois P , Staels B . Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging . Curr Opin Lipidol1999; 10: 151-159 .
18.
Paolisso G , Barbagallo M , Petrella G et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients . Atherosclerosis2000; 150: 121-127 .
19.
Staels B , Koenig W , Habib A et al. Activation of human aortic smooth muscle cells is inhibited by PPAR-alpha but not by PPAR-gamma activators . Nature1998; 393: 790-793 .
20.
Inoue I , Goto S , Mizotani K et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin 1-beta, interleukin-6, cyclo-oxygenase 2 and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPAR-alpha) in primary endothelial cells . Life Sci2000; 67: 863-876 .
21.
Ridker PM , Rifai N , Pfeffer MA , Sacks F , Braunwald E . Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators . Circulation1999; 100: 230-235 .
22.
Rosenson RS , Tangney CC . Anti-atherothrombotic properties of statins . JAMA1998; 279: 1643-1650 .
23.
Wierzbicki AS . Editorial. Is a statin a statin?Int J Clin Pract2001; (in press).
24.
Staels B , Dallongeville J , Auwerx J , Schoonjans K , Leitersdorf E , Fruchart JC . Mechanism of action of fibrates on lipid and lipoprotein metabolism . Circulation1998; 98: 2088-2093 .
25.
Gervois P , Torra IP , Fruchart JC , Staels B . Regulation of lipid and lipoprotein metabolism by PPAR activators . Clin Chem Lab Med2000; 38: 3-11 .
Gelman L , Fruchart JC , Auwerx J . An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer . Cell Mol Life Sci1999; 55: 932-943 .
28.
Wierzbicki AS . Role of lipid lowering in transplantation . Int J Clin Pract1999; 53: 54-59 .
29.
Pedersen TR , Wilhelmsen L , Faergeman O et al. Follow-up study of patients randomised in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering . Am J Cardiol2000; 86: 257-262 .
30.
Lee SJ , Ha MJ , Nguyen P et al. Inhibition of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF-1=CIP-1) in human prostate adenocarcinoma cells . J Biol Chem1998; 273: 10618-10623 .
31.
McPherson R , Tsoukas C , Baines MG , Vost A , Melino MR , Zupkis RV , Pross HF . Effects of lovastatin on natural killer cell function and other immunological parameters in man . J Clin Immunol1993; 13: 439-444 .
32.
Anderson TJ . Assessment and treatment of endothelial dysfunction in humans . J Am Coll Cardiol1999; 34: 631-638 .
33.
Raza K , Thambyrajah J , Townend JN et al. Suppression of inflammation in primary systemic vasculitis restores endothelial function; lessons for atherosclerotic disease?Circulation2000; 102: 1470-1472 .
34.
Lima VC , Lima DS , Sato EI , Hatta F , Miranda F . Endothelial dysfunction in patients with systemic lupus erythematosus . JAm Coll Cardiol2000; 31(Suppl A): 305A-305A (abstract).
35.
Ryan M , Owens D , Kibride B , Collins P , Johnson A , Tomkin GH . Antibodies to oxidised lipoproteins and their relationship to myocardial infarction . Q J Med1998; 91: 411-415 .
36.
Orenkov AN , Kalenich OS , Tertov VV et al. Diagnostic value of immune cholesterol as a marker of athersclerosis . J Cardiovasc Risk1995; 2: 459-466 .
37.
Bili A , Moss AJ , Francis CW et al. Anticardiolipin antibodies and recurrent coronary events . Circulation2000; 102: 1258-1263 .
38.
Papa ND , Raschi E , Morni G et al. Anti-endothelial cell IgG fractions form systemic lupus erythematosus bind to human endothelial cells and induce a pro-adhesive and pro-inflammatory phenotype in vitro . Lupus1999; 8: 423-429 .
39.
Pierangeli SS , Colden-Stanfield M , Xiaowei L , Barker JH , Anderson GL , Harris N . Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo . Circulation1997; 99: 1997-2002 .
40.
Delerive P , de Bosscher K , Besnard S et al. Peroxisome proliferatoractivated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa B and AP-1 . J Biol Chem1999; 274: 32048-32054 .
